Dipyridamole Abbreviated Prescribing Information

Abbreviated Prescribing Information: Dypridisol, Dipyridamole 50mg/5ml Oral Suspension. Consult Summary of Product Characteristics before prescribing. Presentation: A bright yellow suspension with odour of almond, each 5ml containing 50mg of Dipyridamole. Therapeutic Indications: An adjunct to oral anticoagulation for prophylaxis of thromboembolism associated with prosthetic heart valves. Posology and Method of Administration: For oral use only. Dipyridamole suspension should usually be taken before meals. Adults: 300mg to a maximum of 600mg daily in three or four doses. Paediatric population: Dipyridamole is not recommended for children. Contra-indications: Hypersensitivity to any of the ingredients in the product. Special Warnings and Precautions for use: Dipyridamole acts as a vasodilator. It should be used with caution in patients with severe coronary artery disease, including unstable angina and/or recent myocardial infarction, left ventricular outflow obstruction or haemodynamic instability (e.g., decompensated heart failure). Dipyridamole should be used with caution in patients with coagulation disorders. In patients with myasthenia gravis, readjustment of therapy may be necessary after changes in dipyridamole dosage. Patients treated with regular oral doses of dipyridamole should not receive additional intravenous dipyridamole. If pharmacological stress testing with intravenous dipyridamole for coronary artery disease is considered necessary, then oral dipyridamole should be discontinued 24 hours prior to testing. A small number of cases have been reported in which unconjugated dipyridamole was shown to be incorporated into gallstones to a variable extent (up to 70% by dry weight of stone). These patients were all elderly, had evidence of ascending cholangitis and had been treated with oral dipyridamole for several years. Any from the MC, CHM CSM or MHRA: No. Black Triangle notice: Not applicable. A list of very common, common and serious adverse reactions are presented below: Very common: headache, dizziness, diarrhoea and nausea. Common: angina pectoris, vomiting, rash and myalgia. Serious adverse reactions: thrombocytopenia, angioedema, tachycardia, hypersensitivity, hypotension, bronchospasm, post procedural haemorrhage and operative haemorrhage. Refer to the SmPC for full details of adverse reactions. Legal Category: Prescription only medicine. Pack Size and NHS Price: 150ml – £217.61. Marketing Authorisation Number: PL 00427/0133. Marketing Authorisation Holder: Rosemont Pharmaceuticals Ltd, Rosemont House, Yorkdale Industrial Park, Braithwaite Street, Leeds, LS11 9XE, UK. Date of Preparation: [October 2025]